Nabuton (Nabumetone)

Nabumetone is converted in the body to an active metabolite that reversibly inhibits cyclooxygenase (COX‑1 and COX‑2) enzymes. This inhibition lowers prostaglandin production, which are key mediators of inflammation, pain and fever, thereby providing anti‑inflammatory and analgesic effects.

The appropriate dose of Nabuton is determined by the prescribing clinician based on the individual’s condition, severity of symptoms, age, renal and hepatic function, and other concurrent medications. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for nabumetone in pregnancy and lactation are limited. It is generally classified as a drug to be used only if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To order Nabuton, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nabuton (nabumetone) is a prodrug NSAID that offers similar anti‑inflammatory and analgesic efficacy to other non‑selective NSAIDs such as ibuprofen or naproxen, but it may have a slightly different gastrointestinal tolerability profile. Choice of NSAID depends on individual patient risk factors, drug interactions and clinician preference.

Nabuton tablets should be stored at ambient temperature, preferably below 25 °C, in their original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged or the tablets appear discoloured.

Nabuton is taken orally, usually with a full glass of water. It can be taken with or without food, but taking it with food may reduce gastrointestinal discomfort. Patients should swallow the tablet whole and not crush or chew it unless instructed otherwise by a healthcare professional.

Serious risks include gastrointestinal bleeding or ulceration, severe liver injury, acute kidney impairment, cardiovascular events such as heart attack or stroke, and rare allergic reactions like anaphylaxis. Patients should seek immediate medical attention if they experience symptoms such as severe abdominal pain, dark stools, jaundice, sudden swelling, or difficulty breathing.

Nabuton should be avoided in individuals with known hypersensitivity to nabumetone or other NSAIDs, active peptic ulcer disease, severe heart failure, uncontrolled hypertension, significant renal or hepatic impairment, and in patients who are currently taking anticoagulants or other NSAIDs without medical supervision.